Tools   Select Another Resource Report Type

http://tikus.gsf.de

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 23, 2014. Consortium that generated a reference library of gene trap sequence tags (GTST) from insertional mutations generated in mouse embryonic stem (ES) cells. The gene trap database represents a repository of sequences produced in a large scale gene trap screen in mouse ES cells using various gene trapping vectors which are delivered either by electroporation or retroviral infections. A type of retroviral gene trap vector has been developed that can induce conditional mutations in most genes expressed in mouse embryonic stem (ES) cells. The vectors rely on directional site-specific recombination systems that can repair and re-induce gene trap mutations when activated in succession. After the gene traps are inserted into the mouse genome, genetic mutations can be produced at a particular time and place in somatic cells. In addition to their conditional features, the vectors create multipurpose alleles amenable to a wide range of post-insertional modifications. Here they have used these directional recombination vectors to assemble the largest library of ES cell lines with conditional mutations in single genes yet assembled, presently totaling 1,000 unique genes. The trapped ES cell lines, which can be ordered from the German Gene Trap Consortium, are freely available to the scientific community.

Proper citation: German Gene Trap Consortium (RRID:SCR_008532) Copy   

•   Source: SciCrunch Registry

http://research-acumen.eu/

European research collaboration aimed at understanding the ways in which researchers are evaluated by their peers and by institutions, and at assessing how the science system can be improved and enhanced. This FP7 project is a cooperation among nine European research institutes with Professor Paul Wouters (CWTS ����?? Leiden University) as principal investigator.

Proper citation: Acumen Consortium (RRID:SCR_006599) Copy   

•   Source: SciCrunch Registry

http://wiki.c2b2.columbia.edu/califanolab/index.php/BCellInteractome.htm

A network of protein-protein, protein-DNA and modulatory interactions in human B cells. The network contains known interactions (reported in public databases) and predicted interactions by a Bayesian evidence integration framework which integrates a variety of generic and context specific experimental clues about protein-protein and protein-DNA interactions with inferences from different reverse engineering algorithms, such as GeneWays and ARACNE. Modulatory interactions are predicted by the MINDY, an algorithm for the prediction of modulators of transcriptional interactions (please refer to the publication section for more information). The BCI can be downloaded as one tab delimited file containing the complete network (BCI.txt) with each type of interaction explicitly defined.

Proper citation: B Cell Interactome (RRID:SCR_008655) Copy   

•   Source: SciCrunch Registry

http://www.emqn.org

Welcome to the EMQN website. EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines. The European Molecular Genetics Quality Network (EMQN) started in October 1998 after a successful pilot trial. From January 1999 to March 2002, the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515). From April 2002, the network is supported by subscriptions from it users. External Quality Assessment (EQA): There are 26 EQA schemes being offered in 2010. To participate you must be a registered member of the network. For more information on EQA schemes, click the link here. Best Practice: EMQN is actively promoting ''best practice'' meetings on individual diseases. To assist in this process, EMQN will be organising best practice meetings. To participate you must be a registered member of the network. Following the meeting, draft best practice guidelines are produced and publised on this and other related websites, for example, the web site of the UK Clinical Molecular Genetics Society (CMGS). To find out more about best practice click here. Administration: The EMQN is based at the National Genetics Reference Laboratory (Manchester), St Mary''s Hospital, Manchester, The United Kingdom. The Network is co-ordinated and administered by Dr''s Rob Elles and Simon Patton. A management group is responsible for the activities and direction of the network. National partners in different countries help to disseminate information about the network. Quality Policy The EMQN provides a comprehensive range of quality assurance programs for molecular genetics to laboratories and industry worldwide. The European Molecular Genetics Quality Network (EMQN) is committed to helping ensure diagnostic molecular genetic laboratory test results are accurate, reliable and comparable wherever they are produced. The EMQN will provide a high quality and timely service which takes into account the needs and requirements of its users. Objectives To help to raise and maintain the standards of diagnostic clinical molecular genetic testing. To undertake and promote educational activities. To be a leading authority in quality assurance . To design and provide the best possible materials and data management. To design and provide quality reports that are timely and valid. To provide professional support and consultation. To develop new programs as required. To participate in peer review. To strive for continual improvement of the quality system. Sponsor. the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515

Proper citation: European Molecular Quality Network (RRID:SCR_008494) Copy   

•   Source: SciCrunch Registry

http://tripod.nih.gov/npc/

The NCGC Pharmaceutical Collection (NPC) is a comprehensive, publically-accessible collection of approved and investigational drugs for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of disease pathology and intervention. The NPC has already generated several useful probes for studying a diverse cross section of biology, including novel targets and pathways. NCGC provides access to its set of approved drugs and bioactives through the Therapeutics for Rare and Neglected Diseases (TRND) program and as part of the compound collection for the Tox21 initiative, a collaborative effort for toxicity screening among several government agencies including the US Environmental Protection Agency (EPA), the National Toxicology Program (NTP), the US Food and Drugs Administration (FDA), and the NCGC. Of the nearly 2750 small molecular entities (MEs) that have been approved for clinical use by US (FDA), EU (EMA), Japanese (NHI), and Canadian (HC) authorities and that are amenable to HTS screening, we currently possess 2,400 as part of our screening collection. The NPC resource currently consists of (i) the physical collection suitable for high throughput screening (HTS) and (ii) the informatics browser and database. Putting together the physical collection has been surprisingly challenging in terms of the time and effort required in the informatics, compound management and synthetic chemistry related activities required for this endeavor. We provide access to the NPC screening library through collaboration. Please contact our Scientific Director Dr. Chris Austin for additional information. The other half of the NPC resource is the NPC browser. This is a self-contained software that is actively developed and maintained by the informatics group to provide electronic access to the NPC content. The latest version of the NPC browser for various platforms can be downloaded.

Proper citation: NCGC Pharmaceutical Collection (RRID:SCR_006909) Copy   

•   Source: SciCrunch Registry

http://www.ngfn.de/en/start.html

The program of medical genome research is a large-scale biomedical research project which extends the national genome research net (NGFN) and will be funded by the federal ministry of education and research (BMBF) from 2008-2013. Currently the program includes two fields: * Research ** NGFN-Plus: With the aim on combating diseases that are central to health policy, several hundred researchers are systematically investigating the complex molecular interactions of the human body. They are organized in 26 Integrated Genome Research Networks. * Application ** NGFN-Transfer: The rapid transfer of results from medical genome research into medical and industrial application is the aim of the scientists from research institutes and biomedical enterprises that cooperate in eight Innovation Alliances. AREAS OF DISEASE * Cardiovascular disease * Cancer * Neuronal diseases * Infections and Inflammations * Environmental factors

Proper citation: National Genome Research Network (RRID:SCR_006626) Copy   

•   Source: SciCrunch Registry

https://www.guidetopharmacology.org/nciuphar.jsp

Issues guidelines for nomenclature and classification of human biological targets, including targets of current and future prescription medicines. Works to facilitate interface between discovery of new sequences from Human Genome Project and designation of derived entities as functional biological targets and potential drug targets. Developes database which provides access to data on all known biological targets.

Proper citation: NC-IUPHAR (RRID:SCR_006901) Copy   

•   Source: SciCrunch Registry

http://www.zymogenetics.com.

Founded in 1981, ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins. ZymoGenetics is publicly traded (NASDAQ: ZGEN) and headquartered in Seattle, Washington in the historic Seattle City Light Steam Plant building. Our mission is to create novel protein drugs that will significantly help patients fight their diseases. We have contributed to the discovery or development of six recombinant protein products now marketed by other companies. Current programs target viral infection, cancer, inflammatory diseases and bleeding. Our first internally developed product, RECOTHROM Thrombin, topical (Recombinant), was approved by the U.S. Food and Drug Administration (FDA) on January 17, 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now marketed in the United States. We have a promising pipeline of novel therapeutics, which we are developing on our own or in collaboration with partners.

Proper citation: Zymo Genetics (RRID:SCR_008602) Copy   

•   Source: SciCrunch Registry

https://cnprc.ucdavis.edu/

Center for investigators studying human health and disease, offering the opportunity to assess the causes of disease, and new treatment methods in nonhuman primate models that closely recapitulate humans. Its mission is to provide interdisciplinary programs in biomedical research on significant human health-related problems in which nonhuman primates are the models of choice.

Proper citation: California National Primate Research Center (RRID:SCR_006426) Copy   

•   Source: SciCrunch Registry

http://repeatmasker.genome.washington.edu

Welcome to the Department of Genome Sciences, which began in September 2001 by the fusion of the Departments of Genetics and Molecular Biotechnology. Our goal is to address leading edge questions in biology and medicine by developing and applying genetic, genomic and computational approaches that take advantage of genomic information now available for humans, model organisms and a host of other species. Our faculty study a broad range of topics, including the genetics of E. coli, yeast, C. elegans, Drosophila, and mouse; human and medical genetics; mathematical, statistical and computer methods for analyzing genomes, and theoretical and evolutionary genetics; and genome-wide studies by such approaches as sequencing, transcriptional and translational analysis, polymorphism detection and identification of protein interactions. Our chair, Dr. Robert Waterston, joined the department in January 2003. Our department includes both faculty with primary appointments in Genome Sciences, as well as adjuncts in other departments and Seattle institutions. Nine faculty are members of the National Academy of Sciences, including 2001 Nobel Prize winner Dr. Lee Hartwell, who conducted much of his groundbreaking work in the Department of Genetics. Five training faculty are Howard Hughes Medical Institute Investigators. Graduate research in the Department leads to a Ph.D. in Genome Sciences and students may also choose to participate in the Computational Molecular Biology or Molecular Medicine programs. Our department has around 55 - 60 graduate students at any given time and has moved into the new William H. Foege Building.

Proper citation: UW Genome Sciences (RRID:SCR_008562) Copy   

•   Source: SciCrunch Registry

http://www.uv.es/vista/vistavalencia/

The general goal is to achieve a deeper understanding of natural image statistics because from this knowledge it should be possible to explain the behavior of the visual cortex and propose new alternatives in a number of applications in image processing and computer vision in which the basic problem is the choice of an appropriate signal representation. The range of basic and applied topics in which we are currently working include: * Mathematical models of human vision * Statistical image models * Image distortion metrics * Image coding * Motion estimation * Video coding * Image restoration * Color representation

Proper citation: Visual Statistics Group (RRID:SCR_008317) Copy   

•   Source: SciCrunch Registry

http://www.nih.gov/science/brain/

Project aimed at revolutionizing understanding of human brain, to show how individual cells and complex neural circuits interact, enable rapid progress in development of new technologies and data analysis tools to treat and prevent brain disorders. BRAIN Initiative encourages collaborations between neurobiologists and scientists from disciplines such as statistics, physics, mathematics, engineering, and computer and information sciences. Institutes and centers contributing to NIH BRAIN Initiative support those research efforts.

Proper citation: BRAIN Initiative (RRID:SCR_006770) Copy   

•   Source: SciCrunch Registry

http://tulane.edu/som/regenmed/services/index.cfm

The Stem Cell Research and Regenerative Medicine''s Tissue Culture Core provides cells for research use within the department, as well as for distribution to other facilities. The core obtains hMSCs from bone marrow donor samples and expands these cells for research use. The hMSC''s are also characterized for bone, fat and cartilage differentiation, and are stored on site for use. The Tissue Culture Core also handles the expansion and characterization of mouse and rat MSC''s. The animal cells are cultured in a separate area, and never interact with human derived cells. We also have a supply of hMSC''s marked with GFP+, Mito Red and Mito Blue available.

Proper citation: Tulane Stem Cell Research and Regenerative Medicine Tissue Culture Core (RRID:SCR_007342) Copy   

•   Source: SciCrunch Registry

http://mimas.ac.uk/

Mimas is an organization of experts. Our role is to support the advancement of knowledge, powering world-class research and teaching. Technology is at the heart of everything we do. As a nationally designated data center, we host a significant number of the UK''s research information assets. But our core expertise is building applications that enable a wide range of users to make the most of this rich resource from students and researchers working with census data to investigate social inequalities, to scientists using satellite imagery to survey and protect our environment. We have a longstanding relationship with JISC, developing services that support teaching, learning and research and strong connections with research councils, especially the Economic and Social Research Council (ESRC). We also have partnerships with commercial groups, universities and colleges, government agencies, and national libraries and archives. * An organization of experts: We''re experts in technological development, information management, user support, training, project management, and applied research. * What we do: We maintain and support quality services, develop applications and software, provide data hosting and storage, and share our learning. * What we stand for: Four main principles guide our activities: commitment to our users, technological experimentation and innovation, communication within our community, and investment in staff.

Proper citation: Mimas (RRID:SCR_006529) Copy   

•   Source: SciCrunch Registry

http://ecvam.jrc.it/

ECVAM was created by a Communication from the Commission to the Council and the Parliament in October 1991*, pointing to a requirement in Directive 86/609/EEC** on the protection of animals used for experimental and other scientific purposes, which requires that the Commission and the Member States should actively support the development, validation and acceptance of methods which could reduce, refine or replace the use of laboratory animals: Article 7.2: An experiment shall not be performed if another scientifically satisfactory method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available. Article 23: The Commission and Member States should encourage research into the development and validation of alternative techniques which could provide the same level of information as that obtained in experiments using animals, but which involve fewer animals or which entail less painful procedures, and shall take such other steps as they consider appropriate to encourage research in this field. ECVAM has been established in 1992 as a unit of the Environment Institute, part of the Joint Research Centre, and has been transferred to, at that time, newly formed Institute for Health and Consumer Protection in Ispra, Italy in 1998 of which ECVAM is still part of. Duties of ECVAM As defined in the Communication of the European Commission to Council and the European Parliament in October 1991*: 1. To coordinate the validation of alternative test methods at the European Union level. 2. To act as a focal point for the exchange of information on the development of alternative test methods. 3. To set up, maintain and manage a data base on alternative procedures. 4. To promote dialogue between legislators, industries, biomedical scientists, consumer organisations and animal welfare groups, with a view to the development, validation and international recognition of alternative test methods. Moreover, ECVAM should help to expand the JRC''s role in prenormative research. ECVAM thus seeks to promote the scientific and regulatory acceptance of alternative methods which are of importance to the biosciences, through research, new test development and validation, and the establishment of specialised databases, with the aim of contributing to the replacement, reduction and refinement of laboratory animal precedures (in accordance with the 3Rs concept of Russell & Burch***) Due to the political sensitivity of its duties, ECVAM, uniquely at the JRC, has its own Scientific Advisory Committee (ESAC) with participation from all Member States, relevant industrial associations, academic toxicology, the animal welfare movement, as well as other Commission services with interest in the alternatives topic area. The Validation Process Validation is the process by which the reliability and relevance of a procedure are established for a specific purpose. In 1995, based upon experience gained during several recent large-scale validation studies, and in consultation with various international experts (including members of ERGATT), ECVAM published recommendations concerning the practical and logistical aspects of validating alternative test methods (ECVAM workshop report 5). Five main stages in the evolution of new test methods were identified: test development; prevalidation; validation (involving a formal interlaboratory study with the testing of coded chemicals); independent assessment; and progression toward regulatory acceptance. ECVAM has implemented a prevalidation scheme, which includes three main phases: protocol refinement, protocol transfer, and protocol performance. The objective of the prevalidation process is to ensure that any method included in a formal validation study adequately fulfills the criteria defined for inclusion in such a study, so that financial and human resources are used more efficiently, and so that there is a greater likelihood that the expectations of those in the scientific, regulatory and animal welfare communities, who seek the replacement of current animal tests by relevant and reliable alternative methods, will be met. In 2004, ECVAM has published the Modular Approach to the ECVAM Principles on Test Validity (select from the top-menu bar the sector Publications followed by ECVAM Selected Articles) that makes the validation process more flexible, by breaking down the various steps in validation into indipendent modules, and defining for each module the information needed for assessing test validity. Collaborations ECVAMs activities are undertaken in collaboration with numerous laboratories and organisations in the EU Member States, and all over the world. ECVAM also works in close collaboration with other Commission services, such as DG Environment, DG Enterprise, DG Research and DG Health and Consumer Protection. Sponsor. This is a Five years project funded by DG RTD that aims to develop a testing strategy to improve the prediction of oral acute toxicity using non-animals based systems.

Proper citation: European Centre for the Validation of Alternative Methods (RRID:SCR_008504) Copy   

•   Source: SciCrunch Registry

http://eurobonet.pathobiology.eu/cd/

Integration objectives Training and education Standardisation in technology Share of material Web based sharing of information and communication Translational research Spreading excellence objectives Coordinated by Treviso Courses on bone pathology and molecular biology Standard Operation Protocols Web-based discussion forums Research objectives Work packages on: Cartilaginous Tumours (Leiden) Osteogenic Tumours (Munster) Giant Cell Tumours (Oxford) Ewing Sarcoma (Bologna)

Proper citation: Eurobonet (RRID:SCR_008503) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/CSCB/Default.aspx

Biospecimen repository that provides scientists with the opportunity to bank their pluripotent stem cell lines and develops in-house induced pluripotent stem cell (iPSC) lines for distribution. They have developed core capabilities to maintain, characterize, bank, and distribute important stem cell resources. The SCB performs extensive identification and characterization testing for all submitted human induced pluripotent stem cell (iPSC) and mouse embryonic stem cell (mES) lines. The identification and quality control measures include karyotype analysis, microsatellite analysis for parental cell line identity matching, sterility testing, and assessment of viability after cryopreservation. Pluripotency characterizations performed by SCB vary depending upon the distributing repository. * NIGMS iPSCs: Surface antigen expression, Embryoid body formation, Pluritest Gene Expression assay * NINDS iPSCs: Surface antigen expression, Embryoid body formation * NIA mES: Surface antigen expression, Embryoid body formation, Transgene induction Each characterized human iPSC line and mES line released for distribution is provided with a Certificate of Analysis, which includes information regarding characterization and quality of the line, images and links to original publications. The human iPSCs distributed by Coriell are strictly for research purposes and cannot be used in human subjects. All terms described in the Material Transfer Agreement (NIGMS and NINDS Repositories) or Assurance Form (NIA Repository) for the stem cell line must be agreed to prior to using stem cell lines from Coriell.

Proper citation: Coriell Institute Stem Cell Biobank (RRID:SCR_008745) Copy   

•   Source: SciCrunch Registry

http://ctn.uwaterloo.ca/index.html

The Centre for Theoretical Neuroscience (CTN) was recently established at the University of Waterloo. The Centre is a growing research initiative of the University. The Centre consists of several labs focused on various areas of theoretical neuroscience (aka computational neuroscience). At present, the Centre consists of faculty members from Applied Mathematics, Biology, Psychology, Engineering, Philosophy, Statistics, Computer Science, and their students. The Centre has established a unique Graduate Program in theoretical neuroscience and hosts a regular academic colloquium series. The Centre also hosts the annual public Waterloo Brain Day lectures. The Centre is currently expanding, running searches for additional core faculty. The distinguished faculty of the Centre include two Canada Research Chairs and a fellow of the Royal Society of Canada. In addition, the Centre has a number of student researchers, both graduate and undergraduate, and hosts postdocs and visiting researchers. The Centre also hosts a graduate program for students wishing to obtain an officially recognized specialization in theoretical neuroscience. Faculty at the Centre pursue work on purely theoretical questions regarding the foundational principles guiding the function of neural systems, as well as constructing detailed neurobiological models of specific brain areas.

Proper citation: Center for Theoretical Neuroscience; University of Waterloo (RRID:SCR_008747) Copy   

•   Source: SciCrunch Registry

http://www.cytopathology-foundation.org/

Cytopathology Foundation is a non-profit organization dedicated to the health care for the advancement of art and science of Cytopathology dealing with study of cells for proper disease management especially cancer. Cytopathology is a well established diagnostic sub-specialty of pathology. Instead of using surgically removed tissue to arrive at a diagnosis it attempts to identify diagnostic and prognostic information from dispersed cells obtained by non-invasive or minimally invasive techniques. An example, and its greatest success story thus far, is the role it has played in the battle with cervical cancer. The introduction of the Pap smear has contributed immensely to the early diagnosis and significantly decreased mortality of cervical cancer. Activities of the foundation 1. Support the mission statement in general. 2. Support the editorial and publication expenses of CytoJournal. 3. Future activities may include publication and marketing of cytopathology related literature, to generate funds. 4. Support any other scholarly activities in Cytopathology and related areas.

Proper citation: Cytopathology Foundation (RRID:SCR_008467) Copy   

•   Source: SciCrunch Registry

http://www.cienciasecognicao.org

Portal for scientific dissemination, teaching and interdisciplinary research that includes the integration of the sciences of mind, brain and education in Brazil. The contents are in Portuguese. English version coming soon.

Proper citation: Science and Cognition Organization (RRID:SCR_009436) Copy   

•   Source: SciCrunch Registry